colorectal cancer

By the words of Dr. Ruediger Dahlke, cancer is a caricature of today’s modern society as it reflects the dark side ‘growth’. Our civilization is clearly more on the dark side of growth with technology advancing but not with our wellbeing in mind as everything seems to be thriving...

Last week, The European Commission authorizing Comirnaty, a third version of the updated COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to be used in EU countries' vaccination campaigns this autumn to combat yet another Covid-19 variant. But...

Seagen Inc (NASDAQ: SGEN) announced full results from the phase 2 MOUNTAINEER trial, which showed Tukysa (tucatinib) combined with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer (mCRC). ...

Cardiff Oncology Inc (NASDAQ: CRDF) posted new data from Phase 1b/2 trial of onvansertib combined with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line KRAS-mutated metastatic colorectal cancer (mCRC). The data will be shared at the American Society of Clinical Oncology...

Mainz Biomed NV (NASDAQ: MYNZ) has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines to access a portfolio of mRNA biomarkers for future integration into ColoAlert, a detection test for colorectal cancer (CRC).  Mainz is currently...

Idera Pharmaceuticals Inc's (NASDAQ: IDRA) CEO said that clinical trials with tilsotolimod, its synthetic Toll-like receptor 9 (TLR9) agonist, have not yet translated into a new treatment alternative for patients. The Company shared preliminary data from the second 10 patients...

Exact Sciences Corporation (NASDAQ: EXAS) says that Pfizer Inc (NYSE: PFE) will no longer join the Company from November 30 to promote its Cologuard colorectal cancer screening test to health care providers. The decision follows an amendment to a co-promotion agreement signed by the...

Amgen Inc (NASDAQ: AMGN) announced new combination study results from the Phase 1b CodeBreaK 101 study of Lumakras (sotorasib) for KRAS G12C-mutated cancers.  Data will be presented at the AACR-NCI-EORTC 2021 Virtual International Conference on Molecular Targets and...

BioNTech SE (NASDAQ: BNTX) has dosed the first patient with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in Phase 2 clinical trial.  The trial plans to enroll about 200 patients. The open-label Phase 2 trial is investigating BNT122 in stage 2/3...

The FDA has approved Eli Lilly And Co's (NYSE: LLY) new indication for Erbitux (cetuximab injection) combined with Pfizer Inc's (NYSE: PFE) Braftovi (encorafenib) for metastatic colorectal cancer. The approval covers a new indication of CRC with a BRAF V600E...

Boston Scientific Corporation (NYSE: BSX) announced that the EPOCH clinical trial of the TheraSphere Y-90 Glass Microspheres (TheraSphere treatment) met both primary endpoints. The results of a long-term study showed that adding TheraSpheres to a standard chemotherapy regimen could...

Mirati Therapeutics Inc (NASDAQ: MRTX) announced results from the 600mg BID dose cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib in heavily pretreated colorectal cancer patients harboring a KRASG12C mutation. Results showed that adagrasib alone and with cetuximab...

Gritstone bio Inc (NASDAQ: GRTS) has announced updated results from the Phase 1/2 study of GRANITE individualized neoantigen immunotherapy in advanced solid tumors. The immunotherapy is a heterologous prime-boost in combination with Bristol-Myers Squibb Co's (NYSE: BMY...

Amgen Inc (NASDAQ: AMGN) announced data from a Phase 1b/2 study evaluating the combination of Lumakras (sotorasib) with Vectibix (panitumumab) in patients with KRAS G12C-mutated advanced colorectal cancer. Related Link: Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA...

Cardiff Oncology Inc (NASDAQ: CRDF) has announced new data from Phase 1b/2 evaluating onvansertib in combination with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line KRAS-mutated metastatic colorectal cancer (mCRC). Related Content: Cardiff Oncology's Onvansertib...